Previous studies have shown that SMARCA2 has a significant effect on the responsiveness to radiotherapy in non-small cell lung cancer, and its depletion can increase the sensitivity to radiotherapy, suggesting that SMARCA2 may be a potential therapeutic target for sensitization to radiotherapy (Zernickel et al., 2019). The gene discussed is SMARCA2; the disease is non-small cell lung carcinoma.